The performance of companies tied to iconic drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the loss of exclusivity in key territories has introduced substantial risk . Investors are now grappling with the impact of lower-co